Skip to main content

Table 5 Treatment-Emergent Adverse Events Reported by ≥5% of Subjects in Any Treatment Group

From: A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

 FKB327 vial
n = 66
n (%)
FKB327 PFS
n = 63
n (%)
FKB327 AI
n = 66
n (%)
Total
n = 195
n (%)
Nasopharyngitis14 (21.2)15 (23.8)20 (30.3)49 (25.1)
Headache7 (10.6)9 (14.3)2 (3.0)18 (9.2)
Cough5 (7.6)1 (1.6)3 (4.5)9 (4.6)
Oropharyngeal pain4 (6.1)3 (4.8)1 (1.5)8 (4.1)
Injection-site rash004 (6.1)4 (2.1)
  1. AI indicates prefilled autoinjector; PFS prefilled syringe; vial, vial with disposable syringe